|
Targeting ZNF410 for fetal hemoglobin induction in beta-hemoglobinopathies
Targeting ZNF410 for fetal hemoglobin induction in beta-hemoglobinopathies
Background
β-hemoglobinopathies, such as sickle cell disease and β-thalassemias, are genetic disorders characterized by defective hemoglobin production, resulting in anemia and impaired oxygen delivery. These conditions affect millions worldwide, posing significant...
Published: 3/26/2026
|
Updated: 11/29/2025
|
Inventor(s): Daniel Bauer, Divya Vinjamur
Keywords(s):
Category(s): Technology Classifications > Disease Area > Hematology/Oncology, Technology Classifications > Invention Type > Novel Targets
|
